Risk Stratification and Molecular Classification

Dr. Choy explains that pathological evaluation serves dual purposes: establishing diagnosis and determining patient risk stratification for treatment selection. Fortunately, approximately 75% of patients with PEComas present with benign tumors, whereas the remainder require careful risk assessment using established pathological scoring systems.

Malignancy determination involves evaluating specific characteristics: tumor size greater than 5 cm represents adverse risk, while smaller tumors tend toward benign behavior. Additional high-risk features include infiltrative growth patterns, high nuclear grade, mitotic rate exceeding 1 per 50 high-powered fields, necrosis presence, or vascular invasion. Three or more of these factors classify tumors as malignant PEComas, whereas one or two factors indicate uncertain malignant potential rather than truly benign designation, acknowledging metastatic potential even in apparently benign-appearing tumors.

Molecular classification divides PEComas into distinct subgroups: approximately 50% demonstrate TSC1 or TSC2 loss affecting mTOR pathway interactions, although others harbor TFE3 rearrangements. These molecular alterations remain mutually exclusive, with tumors rarely demonstrating both TSC1/2 loss and TFE3 rearrangement simultaneously. This molecular understanding guides treatment selection, particularly for targeted therapy approaches.

Dr. Bouberhan discusses gynecologic-specific considerations, noting initial controversy regarding malignancy criteria application to gynecologic PEComas. Original Folpe criteria included only 4 uterine cases, prompting debate about universal applicability. Subsequently developed relaxed criteria requiring 4 malignant features proved inadequate, with Massachusetts General Hospital research demonstrating misdiagnosis of aggressive tumors. Current World Health Organization criteria mandate three malignant criteria (size >5cm, high nuclear grade, necrosis, high mitotic rate >1 per 50 high-powered fields, or lymphovascular invasion) for malignant gynecologic PEComa classification.

Surgical management varies by malignancy status and patient circumstances. Although hysterectomy represents the most studied approach, fertility-preserving myomectomy has succeeded in selected cases with successful subsequent pregnancies. However, no data supports myomectomy safety for malignant PEComas, with expert consensus favoring hysterectomy for confirmed malignancy. Complete resection with negative margins remains the fundamental surgical principle, though debate continues regarding optimal approaches for benign or uncertain malignant potential tumors.